Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata) for the month of March 2017, specifically dated March 22, 2017. The registrant is a foreign private issuer incorporated in Belgium. The filing serves to incorporate by reference a press release issued on the same date (Exhibit 99.1) into the company's Registration Statements on Forms F-3 and S-8.
Financial Metrics
The provided filing text contains no financial data. It does not report revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing to distribute a press release and does not include a financial statement or performance summary.
Material Changes
The filing text does not disclose specific material changes in financial position or operations. It references a press release (Exhibit 99.1) as the source of material information, but the content of that press release is not included in the provided text.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the press release is incorporated by reference, with the specific exception of a quote by Dr. Piet Wigerinck, which is excluded from the incorporation.
Guidance and Risks: The filing text does not provide any forward-looking guidance, risk factors, contingencies, or details on unusual items.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Missing Content: The actual material event or news is contained in Exhibit 99.1 (the press release), which is referenced but not included in the provided text.
- Exclusion Note: Be aware that a quote by Dr. Piet Wigerinck from the press release was explicitly excluded from the incorporation by reference into the Registration Statements.
- Financial Data: No financial metrics are available in this specific document; investors must consult the company's Form 20-F or the full press release for financial details.